Our present multi-region sequencing study of 10 patients with neuroblastoma shows extensive spatial and temporal intratumour heterogeneity that also affected genes encoding actionable targets, such as ALK and FGFR1, thus, harbouring potential implications for therapeutic target selection. The gene discussed is FGFR1; the disease is neuroblastoma.